Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
| ▸ | CTSG | P08311 | 1/20 | 0.41 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | MYLK | Q15746 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20616487 | 0.82 | ELANE (0.45) | ELANECTSGPRTN3PGRALDH1A1 | |
| SCHEMBL16147746 | 0.77 | KMT2A (0.55) | ALDH1A1MAPTLMNAMAOAMAOB | |
| SCHEMBL11098168 | 0.77 | ELANE (0.40) | ELANECTSGPRTN3PGRALDH1A1 | |
| SCHEMBL628924 | 0.76 | ELANE (0.40) | ELANECTSGPRTN3PGRALDH1A1 | |
| SCHEMBL4848802 | 0.74 | PGR (0.51) | ELANECTSGPRTN3PGRALDH1A1 | |
| SCHEMBL9736357 | 0.72 | KMT2A (0.43) | ALDH1A1MAPTLMNAMAOAMAOB | |
| SCHEMBL28280250 | 0.69 | ALDH1A1 (0.43) | ELANECTSGPRTN3ALDH1A1MAPT | |
| SCHEMBL13041592 | 0.67 | OPRL1 (0.45) | — | |
| SCHEMBL3735180 | 0.67 | OPRL1 (0.42) | PGRALDH1A1MAPTLMNASMN1; SMN2 | |
| SCHEMBL20616449 | 0.65 | PGR (0.49) | ELANECTSGPRTN3PGRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1901776-B1 | NOVEL MEDICINAL COMBINATIONS WHICH ARE USED FOR TREATING RESPIRATORY TRACT DISEASES AND CONTAIN BETA-2 LONG-ACTING AGONISTS AND AT LEAST ONE OTHER TYPE OF ACTIVE SUBSTANCE | BOEHRINGER INGELHEIM INT (DE) | 2012-02-22 | — | — | EP | disclosed |
| EP-1911749-B1 | New long-working Beta-2 agonists and their use as medicine | BOEHRINGER INGELHEIM INT (DE) | 2010-10-27 | — | — | EP | disclosed |
| US-7632834-B2 | Long acting beta-2-agonists and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-15 | — | — | US | disclosed |
| US-20080194550-A1 | LONG ACTING BETA-2-AGONISTS AND THEIR USE AS MEDICAMENTS | BOUYSSOU THIERRY | 2008-08-14 | — | — | US | disclosed |
| US-7375104-B2 | Long acting beta-2-agonists and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-05-20 | — | — | US | disclosed |
| EP-1911749-A1 | New long-working Beta-2 agonists and their use as medicine | Boehringer Ingelheim International GmbH (DE) | 2008-04-16 | — | — | EP | disclosed |
| EP-1901776-A1 | NOVEL MEDICINAL COMBINATIONS WHICH ARE USED FOR TREATING RESPIRATORY TRACT DISEASES AND CONTAIN BETA-2 LONG-ACTING AGONISTS AND AT LEAST ONE OTHER TYPE OF ACTIVE SUBSTANCE | Boehringer Ingelheim International GmbH (DE) | 2008-03-26 | — | — | EP | disclosed |
| EP-1711480-B1 | NOVEL LONG-WORKING BETA-2-AGONISTS AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2007-12-19 | — | — | EP | disclosed |
| US-20070066609-A1 | Long acting beta-2-agonists and their use as medicaments | BOUYSSOU THIERRY | 2007-03-22 | — | — | US | disclosed |
| US-20070037781-A1 | Novel combinations of medicaments for the treatment of respiratory diseases containing long-acting beta-agonists and at least one additional active ingredient | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-02-15 | — | — | US | disclosed |
| WO-2007003554-A1 | NOVEL MEDICINAL COMBINATIONS WHICH ARE USED FOR TREATING RESPIRATORY TRACT DISEASES AND CONTAIN BETA-2 LONG-ACTING AGONISTS AND AT LEAST ONE OTHER TYPE OF ACTIVE SUBSTANCE. | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-01-11 | — | — | WO | disclosed |
| US-7160882-B2 | Long acting β-2-agonists and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-01-09 | — | — | US | disclosed |
| EP-1711480-A1 | NOVEL LONG-WORKING BETA-2-AGONISTS AND USE THEREOF AS MEDICAMENTS | Boehringer Ingelheim International GmbH (DE) | 2006-10-18 | — | — | EP | disclosed |
| US-20050227975-A1 | New long acting beta-2-agonists and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-10-13 | — | — | US | disclosed |
| WO-2005070908-A1 | NOVEL LONG-WORKING BETA-2-AGONISTS AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066609-A1 | Long acting beta-2-agonists and their use as medicaments | ADRB2, ADRB1, CHRM1 | ELANE 2114/4885CTSG 3115/4885PRTN3 2300/4885 |
| US-20050227975-A1 | New long acting beta-2-agonists and their use as medicaments | ADRB2, ADRA2A, ADRB1 | ELANE 1840/4885CTSG 2753/4885PRTN3 2056/4885 |
| US-20070037781-A1 | Novel combinations of medicaments for the treatment of respiratory diseases containing long-acting beta-agonists and at least one additional active ingredient | ADRB2, ADRA2A, ADRB1 | ELANE 376/4885CTSG 1209/4885PRTN3 603/4885 |
| US-20080194550-A1 | LONG ACTING BETA-2-AGONISTS AND THEIR USE AS MEDICAMENTS | ADRB2, ADRB1, CHRM1 | ELANE 2128/4885CTSG 3120/4885PRTN3 2303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.